冬病夏治方治疗COPD稳定期的临床疗效观察(1)
第1页 |
参见附件。
摘要:目的:研究冬病夏治方对稳定期慢性阻塞性肺疾病患者的治疗作用,同时为冬病夏治方治疗COPD稳定期的临床推广提供依据。方法:将40例患者随机分为治疗组和对照组,对照组采用化痰、止咳、平喘等西医常规治疗,治疗组在对照组基础上加用冬病夏治方联合治疗。比较两组患者临床证候、SGRQ评分、肺功能及BODE指数的改变情况。结果: ①研究显示在中医证候积分、SGRQ评分、BODE评分方面,两组治疗前后均有明显的改善(P<0.05,具有统计学意义),但两组组间比较无明显统计学意义(P>0.05)。②6min步行距离、肺功能组内及组间比较无明显统计学意义(P>0.05),治疗显效率、有效率、总有效率组间比较无统计学意义(P>0.05)。③6min步行距离治疗后改善程度治疗组优于对照组(P<0.05,具有统计学意义),中医症状积分及SGRQ评分治疗后两组改善程度比较无明显统计学差异(P>0.05)。结论:在慢性阻塞性肺疾病稳定期运用我院冬病夏治方治疗,与单纯西医常规治疗相比,能有效改善COPD稳定期患者的活动耐力、临床症状,提高生活质量,值得在临床进一步推广应用。
关键词:慢性阻塞性肺疾病;冬病夏治
中图分类号:R563文献标识码:B文章编号:1673-7717(2012)03-0570-03
Effect Observation on Treating Stable Stage of
COPD with Therapy of Winter Disease In Summer
XU Tingzhen 1,YAO Xiaolan2
(1.The First Hospital Attached to Zhejiang University of Traditional Chinese Medicine,Hangzhou 310006,Zhejiang,China;
2.Wenzhou Integrated TCM and Western Medicine Hospital, Wenzhou 325000, Zhejiang,China)
Abstract:Objective: To investigate the guiding sense of “treating winter diseases in summer" in the stable COPD treatment, simultaneously to provide the basis of promoting the therapy in stable COPD treatment. Methods: 40 cases were randomized into two groups.The control group were treated with Westernmedicine,and the treatment group were treated with therapy of "treating winter diseases in summer"on the basis of Westernmedicine with a course of 3 months. Observe and compare the two groups before/after treatment and at the end of 3 months after treatment with Chinese medical clinical aspects, SGRQ grading, pulmonary function and BODE grading. Results: (1) The study revealed medical clinical aspects,SGRQ grading and BODE grading after treatment there was a significant difference (P<0.05) between two groups compared with before treatment, but there was no significant difference (P>0.05) between two groups. (2)6 minute walking test and pulmonary function after treatment, compared with before treatment of the treatment group and the control group there was no significant difference (P>0.05). And there was no significant difference (P>0.05) between two groups with 6MWT, pulmonary function. There was no remarkable difference of the clinical effect rate, the marked improved rate and the total effect improved rate between the two groups (P>0 ......
您现在查看是摘要介绍页,详见PDF附件(2338kb)。